Department of Neurology, University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas, USA
Department of Clinical Research, Valley Baptist Medical Center - Harlingen, Harlingen, Texas, USA.
J Neurointerv Surg. 2021 Feb;13(2):114-118. doi: 10.1136/neurintsurg-2020-016045. Epub 2020 Jul 3.
Endovascular treatment (EVT) is a widely proved method to treat patients diagnosed with intracranial large vessel occlusions (LVOs); however, there has been controversy about the safety and efficacy of incorporating intravenous tissue plasminogen activator (IV tPA) as pretreatment for EVT.
To compare the outcomes of all patients with LVO treated with IV tPA +EVT versus EVT alone within 4.5 hours of stroke onset.
A prospectively collected endovascular database at a comprehensive stroke center between 2012 and 2019 was used to examine variables such as demographics, comorbid conditions, symptomatic/asymptomatic intracerebral hemorrhage (ICH), mortality rate, and good/poor outcomes as shown by the modified Thrombolysis in Cerebral Infarction score and modified Rankin Scale (mRS) assessment at discharge. The outcomes between patients receiving IV tPA+EVT on admission and patients who underwent EVT alone were compared.
Of 588 patients with acute ischemic stroke treated with EVT, a total of 189 met the criteria for the study (average age 70.44±12.90 years, 42.9% women). Analysis of 109 patients from the group receiving EVT+IV tPA (average age 68.17±14.28 years, 41.3% women), and 80 patients from the EVT alone group was performed (average age 73.54±9.84 years, 45.0% women). Four patients (5.0%) in the EVT alone group experienced symptomatic ICH versus 15 patients (13.8%) in the IV tPA+EVT group (p=0.0478); significant increases were also noted in the length of stay for patients treated with IV tPA (8.2 days vs 11.0 days; p=0.0056).
IV tPA in addition to EVT was associated with an increase in the rate of ICH in patients with LVO treated within 4.5 hours and in patients' length of stay. Further research is required to determine whether EVT treatment alone in patients with LVO treated within 4.5 hours is a more effective option.
血管内治疗(EVT)是一种广泛证明的治疗颅内大血管闭塞(LVOs)患者的方法;然而,关于将静脉内组织型纤溶酶原激活剂(IV tPA)作为 EVT 的预处理的安全性和有效性一直存在争议。
比较在卒中发病后 4.5 小时内接受 IV tPA+EVT 治疗的所有 LVO 患者与单独接受 EVT 治疗的患者的结局。
使用 2012 年至 2019 年在综合卒中中心前瞻性收集的血管内数据库,检查人口统计学、合并症、症状性/无症状性颅内出血(ICH)、死亡率和改良溶栓后卒中和改良 Rankin 量表(mRS)评估的良好/不良结局等变量。比较入院时接受 IV tPA+EVT 治疗的患者和单独接受 EVT 治疗的患者的结局。
在接受 EVT 治疗的 588 例急性缺血性卒中患者中,共有 189 例符合研究标准(平均年龄 70.44±12.90 岁,42.9%为女性)。对接受 EVT+IV tPA 的 109 例患者(平均年龄 68.17±14.28 岁,41.3%为女性)和单独接受 EVT 的 80 例患者(平均年龄 73.54±9.84 岁,45.0%为女性)进行了分析。单独接受 EVT 治疗的患者中有 4 例(5.0%)发生症状性 ICH,而接受 IV tPA+EVT 治疗的患者中有 15 例(13.8%)(p=0.0478);接受 IV tPA 治疗的患者的住院时间也明显延长(8.2 天 vs 11.0 天;p=0.0056)。
在卒中发病后 4.5 小时内接受 LVO 治疗的患者中,IV tPA 联合 EVT 治疗与 ICH 发生率增加以及患者住院时间延长有关。需要进一步研究以确定在卒中发病后 4.5 小时内接受治疗的 LVO 患者单独接受 EVT 是否是一种更有效的治疗选择。